TP53 and esophageal adenocarcinoma: For the first time, we demonstrate APR‐246 anti‐tumor efficacy in PDO cultures derived from TP53 missense mutant colorectal cancer (colo‐PDO) (Fig 2F) and esophageal adenocarcinoma (eso‐PDO) (Appendix Fig S2D), as assessed by the ATP‐based CTG assay.